Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: schadenfreude who wrote (27196)	1/5/1999 12:41:00 PM
From: Machaon	Respond to of 32384

<< These financings solidify the balance sheet, but they don't help the earnings. >> The earnings report will show the 4th quarter revenues, and Ligand's loss for the quarter. The more revenues that they take in, the less the loss. The cash from Elan and the $12 million taken in during the 4th quarter of 1998 for the warrants, will have a very positive effect on the 4th quarter earnings report's bottom line, IMHO. In clinical stage biotechs, the market looks at things like revenues, cash on hand, available funds, loss for the quarter, etc. Especially in these times where a bunch of biotechs are faced with a hostile financing climate. Sorry if my misuse of terms caused any confusion.